Beta-blocker therapy after myocardial infarction
Beta-blocker therapy after myocardial infarction
Led by Dr Stella Talic and Professor Dion Stub
This research investigated the effectiveness and outcomes of beta-blocker therapy after myocardial infarction (MI), with a focus on all-cause mortality, cardiovascular mortality, and recurrent MI. The work included three complementary studies:
- State-of-the-Art Review: Synthesised the current evidence on beta-blocker therapy post-MI, including efficacy across different LVEF subgroups and patient populations.
- Nested Case-Control Study Using the VCOR Registry: Analysed real-world data from the Victorian Cardiac Outcomes Registry, examining associations between beta-blocker use, LVEF, and clinical outcomes in contemporary practice.
- Umbrella Review: Conducted an overview of systematic reviews and meta-analyses to evaluate the robustness of evidence, stratified by study design, patient subgroups, and risk of bias.
These studies collectively aimed to inform LVEF-stratified, individualised treatment decisions, support guideline refinement, and provide practical recommendations for clinicians.
Outputs
- Cataldo Miranda P, Gasevic D, Trin C, Stub D, Zoungas S, Kaye DM, Orman Z, Eliakundu AL, Talic S. Beta-Blocker Therapy After Myocardial Infarction. JACC: Advances. 2025 Mar;4(3):101582. doi: 10.1016/j.jacadv.2024.101582.
- Cataldo-Miranda P, Koh HJW, Stub D, Zoungas S, Kaye DM, Gasevic D, Brennan A, Dinh D, Lefkovits J, Nanayakkara S, Chew DP, Talic S. Beta-blocker therapy and all-cause mortality after a coronary event: A matched nested case-control study using the Victorian Cardiac Outcomes Registry linked data. Current Problems in Cardiology. 2026 Aug;51(8):103340. doi: 10.1016/j.cpcardiol.2026.103340.